The goal of the colloquium is to showcase the synergistic interaction between chemistry, biology, pharmacology, and bioinformatics in the process of drug development. Our aim is to promote a professional dialogue between students and experts from different disciplines interested in the processes of drug discovery and development. This conference provides a platform for undergraduates, graduate students, and post-doctoral fellows to present their research. This conference will also include a professional development session, as well as providing great networking opportunities.
Virtual Conference Dates : July 15-16, 2021
Call for Participation
The Conference Program Committee invites you to submit an abstract for either a poster or oral presentation. Abstracts are limited to 300 words in length.
For registration click here
Oral abstract deadline June 25th, 2021
Poster abstract deadline July 2nd, 2021
Ruth Roberts, Ph.D.
Co-founder and Director, ApconiX
Dr. Ruth has 25 years of experience in leading roles in drug safety within large pharma. Dr. Ruth is also Chair and Director of Drug Discovery at The University of Birmingham, UK and was previously Global Head of Regulatory Safety at AstraZeneca.
With over 140 publications in peer-reviewed journals, she is former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and President of the Academy of Toxicological Sciences. Dr. Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology. Dr. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development.
Binodh DeSilva, Ph.D.
Vice President, Lead, Discovery and Optimization, Small Molecule Drug Discovery, Bristol Myers Squibb
Dr. Binodh is vice president and lead for Discovery and Optimization as part of Bristol Myers Squibb’s Small Molecule Drug Discovery organization, where she helps the company leverage technological solutions to deliver comprehensive in-vitro data, from concept to drug candidate.
Dr. Binodh joined Bristol Myers Squibb in 2010 to lead immunochemistry and biomarker development. In that role, she led the development, validation and implementation of immunoassays, biologicals and other techniques to quantify biopharmaceutical drugs and related compounds in biological samples. Prior to joining Bristol Myers Squibb, she held leadership positions at Amgen, including head of the protein bioanalytical group. Dr. Binodh has published and presented extensively in her field, including lead author on “Recommendations for the Bioanalytical Method Validation of Ligand-binding Assays to Support Pharmacokinetic Assessments of Macromolecule,” a paper that helped the FDA incorporate ligand binding assay criteria into its bioanalytical guidance.
Andy Vick, Ph.D.
Corporate Vice President, Safety Assessment Midwest at Charles River Laboratories
Dr. Vick joined Charles River with the acquisition of WIL Research in April 2016. He leads the strategic management and operational oversight of the Ohio sites (Ashland, Cleveland, and Spencerville) as well as the Skokie, Illinois site, focusing on the integration with the Safety Assessment sites in North America to broaden Charles River’s drug discovery and development portfolio. Prior to joining Charles River, Dr. Vick was Vice President, Analytical Services for WIL Research, overseeing scientific, operational, and financial aspects of the analytical, formulations, bioanalytical, drug metabolism and pharmacokinetic services for the sites in the US. He is an active member of the American Association of Pharmaceutical Scientists (AAPS), and is currently serving on the Executive Committee of the AAPS Foundation. Dr. Vick is also President of the Board of The Ohio State University’s College of Pharmacy. He received his B.S degree in Zoology and Ph.D. degree in Pharmaceutics and Pharmaceutical Chemistry from The Ohio State University in Columbus, OH.
Chalet Tan, Ph.D.
Associate Professor of Pharmaceutics and Drug Delivery, University of Mississippi
Dr. Tan obtained her Ph.D. degree in Pharmaceutics from the University of Georgia in Athens, Georgia. She received postdoctoral training in cancer biology and immunology at the National Cancer Institute in Bethesda, Maryland. Dr. Tan joined the University of Mississippi School of Pharmacy in 2016. With strong expertise in nanomedicine, pharmacokinetics, and cell signaling, Dr. Tan has a multidisciplinary laboratory that focuses on targeted drug delivery and immunotherapy for cancers and infectious diseases. The work in her group has been continuously supported by the National Institutes of Health (NIH) for over a decade. Dr. Tan is frequently invited to serve on NIH study sections and special emphasis panels as a grant reviewer.